Mankind Pharma Q2 Revenue Jumps 17.3% on Global Surge
Mankind Pharma reported a 17.3% rise in Q2 FY27 revenue to Rs 4,338 crore, driven by a 33% surge in international sales and strong domestic growth.

Mankind Pharma delivered 33% international revenue growth and 17.3% domestic revenue growth in Q2 FY27. The pharmaceutical company’s revenue from operations rose 17.3% year-on-year to Rs 4,338 crore for the quarter, with exports rising 32.7% to Rs 681 crore and domestic revenue up 14.8% to Rs 3,657 crore. For the first half of FY27, total revenue grew 15.1% to Rs 8,368 crore, with domestic revenue at Rs 7,082 crore and exports at Rs 1,286 crore.
International revenue grew 33% year-on-year in Q2, driven by strong performance from both Mankind and BSV’s overseas businesses. The company launched one new product in the US during the quarter, taking its cumulative number of product launches in that market to 50.
Profitability and Margin Expansion
Earnings before interest, taxes, depreciation and amortisation (EBITDA) margin expanded 210 basis points to 27.1% in Q2. Profit after tax (PAT) margin improved 240 basis points to 16.5%. Diluted earnings per share increased 38.9% year-on-year to Rs 17.2.
For the first half of the fiscal year, profitability metrics showed similar strength. EBITDA margin widened 230 basis points to 26.7%, and PAT margin advanced 210 basis points to 15.4%. Diluted EPS for the half-year climbed 34.6% to Rs 30.9.
Brand Performance and Market Share
Key brands across therapy areas delivered robust growth, outperforming the market. The company retained its number one ranking in the Indian Pharmaceutical Market for the ninth consecutive year, with a prescription share of 15.2% and prescriber penetration of 84.4% for the period ending August 2026.
Secondary sales grew 15.7%, exceeding the Indian Pharmaceutical Market’s growth of 14.2%. The company outperformed the market by 1.1 times in both chronic and acute therapies. Modern trade and e-commerce contributed 18% of the business in Q2, up from 12% a year earlier.
Growth was led by several high-performing brands. A selection of key brand growth rates is shown below.
| Therapy Area | Brand | Growth Rate |
|---|---|---|
| Acute | Pantakind | 31% |
| Acute | Dydroboon | 19% |
| Acute | Cefakind CV | 18% |
| Acute | Nurokind LC | 18% |
| Chronic | Pangraf | 60% |
| Chronic | Placida | 28% |
| Chronic | Telmikind AM | 16% |
| Chronic | Glizid M | 15% |
| BSV Portfolio | Humog | 51% |
| BSV Portfolio | Lonopin | 45% |
| BSV Portfolio | Anti D | 37% |
| BSV Portfolio | ASVS | 45% |
Cardiac and anti-diabetes brands registered growth of 18.7% and 15.8%, respectively. In acute therapies, gastroenterology grew at 1.3 times the market rate, while vitamins, minerals and nutrients expanded at 1.4 times that rate. Anti-infectives showed growth accelerating to 5.4% in Q2 from 3.6% in the preceding quarter.
The number of brands generating annual sales of more than Rs 50 crore increased to 63 as of September 2026, from 54 in FY26. Brands with sales exceeding Rs 100 crore rose to 26 from 22.
Strategic Growth and Market Position
The company's secondary sales growth of 15.7% represented 1.1 times the market’s growth rate. Secondary sales of specific brands like Preganews and Ova News increased 14% and 10%, respectively, during the quarter.
This operational strength has been reflected in the company's share performance. Mankind Pharma shares gained 10.58% over the last week and 15.11% in 2026. Over longer periods, shares were up 3.10% over the last one year and 41.67% over the last three years.
The company's recent acquisition of Armed Cell Therapeutics marks a strategic entry into Next-Generation CAR-T therapies.





